A robust retrospective VA study further supports the use of the over-the-counter vitamin B3 derivative nicotinamide as non-melanoma skin cancer prophylaxis, particularly among those initiating it after a first skin cancer where risk was reduced by over 50%. | Breglio, JAMA Dermatol 2025
